Holen Sie sich die Stockscreener-App
118.48
0.23%
0.27
Vorhandelsmarkt:
118.02
-0.46
-0.39%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Chinese Research Org. Says Gilead Infringed COVID Patent - Law360
Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga
Gilead to present promising data for Trodelvy in breast cancer at ESMO - Investing.com
Gilead to present Trodelvy breast cancer data at ESMO 2025 - StreetInsider
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades' - Benzinga
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 - Business Wire
Yousif Capital Management LLC Sells 2,855 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer - FirstWord Pharma
ADAPT: Accelerating Disability Awareness & Progress Together - Gilead Sciences
OFI Invest Asset Management Sells 86,817 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Transcendent Capital Group LLC Invests $432,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Position Boosted by Sivik Global Healthcare LLC - MarketBeat
Natural Investments LLC Has $317,000 Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Lmcg Investments LLC Has $1.97 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline - Yahoo
Conning Inc. Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Fourpath Capital Management LLC Reduces Stake in Gilead Sciences, Inc. $GILD - MarketBeat
3Chopt Investment Partners LLC Acquires 3,318 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Aberdeen Group plc - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Unloaded Rep. Val T. Hoyle - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Gilead: Incorporating Longer Biktarvy Runway - Morningstar
Gilead's HIV Portfolio Has a Long Runway and Supports a Wide Moat - Morningstar
Cantor Fitzgerald Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Blair William & Co. IL Decreases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Trifecta Capital Advisors LLC Has $339,000 Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
TFR Capital LLC. Makes New $283,000 Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Callan Family Office LLC Purchases 63,300 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Tectonic Advisors LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Maryland State Retirement & Pension System Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
US Bancorp DE Sells 22,670 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Vontobel Holding Ltd. Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Can Gilead Sciences Inc. hit a new high this monthWeekly Investment Report & Fast Moving Trade Plans - newser.com
Real time social sentiment graph for Gilead Sciences Inc.July 2025 Setups & Weekly Breakout Stock Alerts - newser.com
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025 - BioSpace
"Taking possibility back" across oncology’s toughest frontiers - statnews.com
Gilead Sciences To Release Third Quarter 2025 Financial Results On Thursday, October 30, 2025 - TradingView
Gilead blocks HIV drug generics for more than 10 years - Life Sciences Intellectual Property Review
A Look Inside Gilead's Inflammation Pipeline - Gilead Sciences
Cantor Fitzgerald Adjusts PT on Gilead Sciences to $135 From $129, Maintains Overweight Rating - MarketScreener
Can Gilead Sciences Inc. stock deliver consistent earnings growthMarket Trend Summary & Real-Time Market Sentiment Reports - newser.com
Fluent Financial LLC Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Kingswood Wealth Advisors LLC Reduces Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Given "Buy (B)" Rating at Weiss Ratings - MarketBeat
Citigroup Maintains Gilead Sciences (GILD) Buy Recommendation - Nasdaq
Gilead Sciences Rallies After Trump Partnership News Is the Growth Story Just Beginning - Yahoo Finance
GILD: Citigroup Raises Price Target for Gilead Sciences Amid Buy Rating | GILD Stock News - GuruFocus
Greed Is a Hell of a Drug - Truthdig
Multiple Myeloma CAR-T Market Set for Rapid Growth Driven by BCMA-Targeted Therapies and Innovative Advances - GlobeNewswire Inc.
RBC Capital raises Gilead Sciences stock price target to $100 on Yeztugo launch - Investing.com
Royal Bank Of Canada Increases Gilead Sciences (NASDAQ:GILD) Price Target to $100.00 - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $135.00 at Citigroup - MarketBeat
Citigroup Adjusts Price Target on Gilead Sciences to $135 From $125, Maintains Buy Rating - MarketScreener
RBC Lifts Price Target on Gilead Sciences to $100 From $98, Keeps Sector Perform Rating - MarketScreener
Prime Capital Investment Advisors LLC Decreases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
WESPAC Advisors LLC Purchases 7,248 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Settlements Push Back US Biktarvy Competition To 2036 - insights.citeline.com
Triasima Portfolio Management inc. Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Friedenthal Financial Purchases Shares of 9,152 Gilead Sciences, Inc. $GILD - MarketBeat
Valeo Financial Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
DAVENPORT & Co LLC Sells 16,332 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Sees Relative Strength Rating Rise To 72 - Investor's Business Daily
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years - Benzinga
Gilead Sciences : Third Quarter 2025 Estimated Acquired IPR&D - MarketScreener
Gilead Sciences stock rises as Bernstein reiterates Outperform rating - Investing.com
SteelPeak Wealth LLC Lowers Position in Gilead Sciences, Inc. $GILD - MarketBeat
KLP Kapitalforvaltning AS Purchases 20,100 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy - Zacks Investment Research
Going Beyond – Ending the HIV epidemic by 2030 : From Belgium to the EU - Gilead Sciences
Shell Asset Management Co. Buys 22,026 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead inks trio of Biktarvy patent settlements, waylaying US copycats until 2036 - Fierce Pharma
Gilead Sciences 2025: Slow and steady - PharmaLive
Simplicity Wealth LLC Boosts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Merit Financial Group LLC - MarketBeat
Is Gilead Sciences Inc Gaining or Losing Market Support? - Sahm
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway - Stocktwits
Gilead Gets HIV Generic Drugs Barred From Market Until 2036 - Law360
0.85%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):